Therapy News and Research

RSS

Shire receives marketing approval from FDA for VPRIV

Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.

27 Feb 2010

Federal officials focus on radiation practices at Florida clinic; Medical scan makers announce new efforts to prevent mistakes

Medicare regulations require that when patients receive some types of highly specialized cancer treatments, their radiation oncologist must be on site. But The New York Times reports that federal officials are investigating a Florida cancer clinic that billed Medicare for such treatments while the doctors were absent, sometimes on overseas trips.

27 Feb 2010

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

The drug dabigatran was as effective as the currently recommended drug – warfarin – in preventing a subsequent stroke among people with atrial fibrillation and prior stroke or transient ischemic attack – and it did so with less bleeding according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia.

27 Feb 2010

Gene signature may help identify risk of colon cancer recurrence

A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study by Vanderbilt-Ingram Cancer Center researchers.

26 Feb 2010

Carotid artery stenting and carotid endarterectomy equally safe and effective for people at risk for stroke

Carotid artery stenting, a less invasive alternative to surgery on the carotid artery (carotid endarterectomy), is equally safe and effective for people at risk for stroke as carotid endarterectomy, according to a major new study presented today at the 2010 International Stroke Conference in San Antonio, Texas.

26 Feb 2010

Gaucher disease: FDA approves VPRIV

The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.

26 Feb 2010

Hypnosis may help reduce pain and suffering in metastatic breast cancer patients

Hypnosis can help alleviate the pain and suffering experienced by women being treated for breast cancer, according to a study by a University at Buffalo School of Social Work professor.

26 Feb 2010

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Arena Pharmaceuticals, Inc. announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for the FDA to complete its review of the NDA.

26 Feb 2010

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.

26 Feb 2010

Salmonella-infected mice help understand how symptoms of HLH develop

A new University of Colorado at Boulder study shows mice infected with the bacteria salmonella develop clinical signs consistent with a deadly and poorly understood human inflammatory disease, a finding that may lead to new therapies.

26 Feb 2010

New strategy against Botulinum toxin

A study involving the world's deadliest substance has yielded a new strategy to clear toxins from the body-which may lead to more efficient strategies against toxins that may be used in a bioterrorist event, as well as snake bites, scorpion stings, and even some important chronic diseases.

26 Feb 2010

Prevention of heart attacks: Resveratrol appears to exhibit broader action than aspirin

With the realization that half of the people experiencing a sudden mortal heart attack were taking aspirin on the day of their demise, and the fact that higher-than-recommended doses of aspirin are needed to prevent blood clot formation in coronary arteries, coupled with an announcement that the red wine molecule resveratrol (rez-vair-ah-trawl) may protect from sudden mortal heart attack in a superior fashion to aspirin, suggests re-evaluation of cardiology's current instruction regarding prevention of heart attacks, says Nate Lebowitz MD, cardiologist with the Advanced Cardiology Institute in Ft. Lee, New Jersey.

26 Feb 2010

Integrative oncology program aims to address cancer patients' needs from every angle

The very instant Penny Kukovec was diagnosed with breast cancer her world permanently changed. Suddenly, it felt as if her life was out of her control. She felt powerless and overwhelmed. There were so many unanswered questions.

26 Feb 2010

Nanotechnology to tackle side effects and drug resistance in treatment of cancer

Huixin He, associate professor, nanoscale chemistry at Rutgers University, Newark, and Tamara Minko, professor at the Rutgers Ernest Mario School of Pharmacy, have developed a nanotechnology approach that potentially could eliminate the problems of side effects and drug resistance in the treatment of cancer. Under traditional chemotherapy, cancer cells, like bacteria, can develop resistance to drug therapy, leading to a relapse of the disease.

26 Feb 2010

Paralysis from a stroke: Rare nerve transfer improves mobility

The Plastic Surgery Center today announced the successful results of a rare nerve transfer performed for the first known time on a stroke patient to reverse paralysis. Following the procedure, which was led by Dr. Andrew Elkwood, M.D., 47-year old Vincent Filipini is now able to lift, move and bend his once paralyzed arm. Mr. Filipini continues to show improvement in his mobility.

26 Feb 2010

Intracranial stenting, intra-arterial tPA more effective than other urgent ischemic stroke treatments

Techniques that keep brain arteries open (intracranial stenting) or inject clot-busting drugs directly to the brain (intra-arterial tPA) may be more effective than other urgent ischemic stroke treatments, researchers said at the American Stroke Association's International Stroke Conference 2010.

26 Feb 2010

MITA announces new radiation dose safeguards for expansively addressing patient safety in medical imaging

As part of its ongoing commitment to ensuring safe, appropriate and effective medical imaging and radiation therapy, the Medical Imaging & Technology Alliance (MITA) announced today a new industry-wide commitment to more expansively address patient safety in medical imaging by including new radiation dose safeguards.

26 Feb 2010

Anthem Blue Cross' payment cuts for physical therapy services will financially prevent providers from offering care

Patients enrolled in Anthem Blue Cross of California may be in for a rude and costly awakening the next time they visit a physical therapist. According to the California Physical Therapy Association, the insurance company is slashing payment for physical therapy services to a rate so low it is financially impossible for many physical therapists to continue providing care to enrollees of Anthem Blue Cross.

26 Feb 2010

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

EKOS Corporation announced today that Dr. David W. Newell, Co–Executive Director, Swedish Neuroscience Institute (Seattle, WA) presented a SNI clinical study known as ‘SLEUTH’ (Safety of Lysis with Ultrasound in the Treatment of Intracerebral (ICH) and Intraventricular Hemorrhage (IVH) at the American Heart Association International Stroke Conference (San Antonio, TX).

26 Feb 2010

Therapy News and Research

Shire receives marketing approval from FDA for VPRIV

Federal officials focus on radiation practices at Florida clinic; Medical scan makers announce new efforts to prevent mistakes

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Gene signature may help identify risk of colon cancer recurrence

Carotid artery stenting and carotid endarterectomy equally safe and effective for people at risk for stroke

Gaucher disease: FDA approves VPRIV

Hypnosis may help reduce pain and suffering in metastatic breast cancer patients

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Salmonella-infected mice help understand how symptoms of HLH develop

New strategy against Botulinum toxin

Prevention of heart attacks: Resveratrol appears to exhibit broader action than aspirin

Integrative oncology program aims to address cancer patients' needs from every angle

Nanotechnology to tackle side effects and drug resistance in treatment of cancer

Paralysis from a stroke: Rare nerve transfer improves mobility

Intracranial stenting, intra-arterial tPA more effective than other urgent ischemic stroke treatments

MITA announces new radiation dose safeguards for expansively addressing patient safety in medical imaging

Anthem Blue Cross' payment cuts for physical therapy services will financially prevent providers from offering care

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News